TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Average Daily Wear Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Eye Discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loading Dose Maximum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery-Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Viral Load Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Holter monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Nasal Polyp Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breastfeeding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Ocular Itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children carriers of giant viruses in their digestive tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of OSA in COPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perceived Risk of Breast Cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: change in daytime and night-time mean systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in reflux symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction of current status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distance Walked in Six Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with a molecular diagnostic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PT-INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum observed plasma concentration at steady state (Cmaxss) - clindamycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from the start to the end of one dosing interval at steady state (AUCss) - clindamycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration at steady state (Cmaxss) - Trimethoprim-Sulfamethoxazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from the start to the end of one dosing interval at steady state (AUCss) - Trimethoprim-Sulfamethoxazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum high-sensitivity CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Retinal Oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar Spine Bone Mineral Density Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in markers of bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of plaques in the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nocturnal mean arterial blood pressure (nMAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local-regional, progression-free (LRPF) rate
Endpoint domain: Mortality/survival
Primary endpoint: Relative change in standard uptake volume (SUV) peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Central Retinal Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Change in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total body vitamin A stores in the sub-toxic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major Molecular Response (MMR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reported Adverse Events (AEs) at 30 day Follow-Up
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline to Day 17 in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline to Day 17 Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Experienced Toxicity to the Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients With an Immune Response to p53-infected Autologous Dendritic Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak Immune Response as Measured by Number of Spots Per Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of individual types of amino-acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance rate of participants to a 10-week virtual reality-based dance training
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in incidence of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cognitive functions during single and dual tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serology-confirmed influenza infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hemoglobin (Hb) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maintenance of initial treatment phase Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average daily abdominal pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Initial Anxiety degree
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Initial Fear of Cancer degree
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Picture Sequence Memory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Flanker test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: List Sorting test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pattern Comparison Processing Speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Walking Executive Function Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Timed up-and-go
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Ideal intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of hypnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Lafutidine and Irsogladine maleate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration-time curve (AUClast) of Lafutidine and Irsogladine maleate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurologic deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Original Site Failures
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of New Distant Failures
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic Equivalent of Task-minutes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unsatisfactory clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sustained Viral Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the curve from serial Indomethacin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in MAS grade for Wrist flexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pathologic Complete Response Rate (<pT0>)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of opioid analgesics used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of opioid analgesics remaining
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Anticoagulant-related Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immunological response measured by increased numbers of peptide specific CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of vaccine measured by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD Clinical Global Impressions Scale - Severity (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Clinical Global Impressions Scale - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of participants with postdural puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants reporting health symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Change in brain structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline of Urine Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: COPD Assessment Test (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6 min walk test: Distance (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tear Film Osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Assessed Progression-Free Survival (invPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Disclosure of HIV status to sex partners
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Unprotected sexual encounters
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in plasmatic concentration of myeloperoxidase and elastase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pregnancy Success
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants experiencing clinical and laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with TEAEs Potentially Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Changes in Clinically Significant (CS) Laboratory Value Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measure 66 (GMFM 66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response as measured by tetramers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response as measured by genomic studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response as measured by flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically significant infection requiring treatment and hospitalisation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Onset, magnitude, and change over time of ARC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perception of Physician Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systemic inflammatory signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity of Inactivated, Split-Virion Influenza Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of Inactivated, Split-Virion Influenza Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in knowledge attitudes & practices related to Cardiovascular risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Estimate the Cardiovascular risk factor burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing grade 3-5 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Half-Life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the meal stimulated C-peptide curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anti-factor Xa plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shared Care questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endogenous Glucose Production Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects achieving LDL-C target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mucosal impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Non-relapse mortality at 100 days post transplant
Endpoint domain: Mortality/survival
Primary endpoint: Accommodative Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in day-time ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of T cells expressing the HLA-G receptor ILT2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of circulating soluble HLA-G
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endothelium-dependent arterial dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5-year survival after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Self-reported Days of Methamphetamine Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart-Failure Hospitalization or All-Cause Death
Endpoint domain: Mortality/survival
Primary endpoint: Safety Composite Event Within the First 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complications associated with percutaneous lung biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability and Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Number of Bleeding Episodes Per Patient Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Bleeding-related Exposure Days Per Patient Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Exposure Days Per Patient Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of protein markers in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in glycosylated haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequacy of enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Fatigue Visual Analog Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: İnsomnia Visual Analog Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: ischemic stroke recurrence events
Endpoint domain: Mortality/survival
Primary endpoint: BI (Barthel Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pulmonary Function Test Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mortality at discharge
Endpoint domain: Mortality/survival
Primary endpoint: Leg pain NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) at 12 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Episodes With Symptoms of Unsteadiness/Dizziness Reduced From Moderate/Severe to None/Mild
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of euploid embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Forced Expiratory Volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Healing of apical periodontite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain measured by Brief Pain Inventory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported improvement on the Patient's Global Impression of Improvement scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional changes of RV after the race
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apparition of VEB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Abstinence From Tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ixabepilone toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Gastrocnemius muscle length (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Predict AKI risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection rate of sentinel lymph nodes (SLN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Diagnosis of a thromboembolic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Health related quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase of Hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fetal thymus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive state
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning